

HurriChem™ Nebulizer

A complete treatment
solution for **PIPAC**

Pressurized Intraperitoneal
Aerosolized Chemotherapy

with the
**SurgiChem™ Dual
Injector Pump**



HurriChem™ Nebulizer

The **HurriChem** device nebulizes liquids via a stainless steel wand and high-pressure tubing when combined with an injector pump system. It is a CE-approved, single-use device used to deliver liquid medications during laparoscopy/minimally invasive surgery. **HurriChem** allows physicians to provide therapies such as PIPAC and Electrostatic PIPAC. **HurriChem** is inserted via a minimal access port with a minimum diameter of 10 mm.

Specifications

Maximum injector pump pressure:
200 psi/13.8 bar

Median droplet size:
3.6 microns

Diffusion angle:
up to 80 degrees

Suggested flow rate:
0.5 ml/second

Material:
Stainless steel wand, polyurethane with nylon braid tubing, polycarbonate luer connections

Packaging:
1 nebulizer and 1 high pressure tubing set



Ordering Information

Description:

HurriChem Device Kit

Part Number:

PDT-5500

(CE-approved, non-U.S. use only)

ThermaSolutions

1889 Buerkle Road
White Bear Lake, MN 55110

USA

Phone: +1 877 952 6100

Fax: +1 651 209 3903

Email: info@thermasolutions.com

Scan Code for
HurriChem™ video



ThermaSolutions Europe B.V.

Takkebijsters 41
4817 BL Breda

THE NETHERLANDS

Phone: +31 76 579 1144

Email: emea@thermasolutions.com

The HurriChem™ is intended for the minimally invasive administration of aerosolized liquids. Warnings: Read the IFU. Failure to read IFU could result in harmful effects to the user, patient, and/or product. The HurriChem™ is sterile. Inspect the device & packaging carefully, do not use if the package is damaged or the expiration date has passed. Device should only be used by a trained physician. The HurriChem™ should only be operated to a maximum pressure of 200 psi and used with a liquid injector system capable of delivering flow of .5 ml to 1 ml/second. Flow rate greater than .5 ml/sec recommended for proper aerosolization and should not exceed a pressure of 200 psi or greater. If combined with other equipment, also follow the warnings and cautions of the other device. Follow hospital internal guidelines for handling and disposal of any contaminated materials, products, and pharmaceuticals. Designed for single use only; do not re-sterilize to avoid risk of material damage, microbiological contamination, or infection. Do not modify, as product may not work as intended if altered. Use only with supplied high-pressure tubing. Ensure the integrity of the pneumoperitoneum prior to insertion. Any medicinal substances used with the device are at the discretion of the physician. Off-label use is not promoted. Cautions: Ensure the high-pressure tubing is connected properly and securely to both the HurriChem™ and any injector pump or manual syringe. Store in a dry and clean environment. Maintain sterility of the components after removing from the packaging. When using a camera cover over the system, contain the entire length of the assembled device within the cover. Insert the device through a trocar/port under direct visualization to avoid unintended contact/damage to internal tissue. The device requires a 10 to 12mm port for access. The access port must maintain a secure fit on the abdominal wall throughout the use of the device. Luer lock connections should be ISO 594-2 compliant. A Closed Aerosol Waste System (CAWS) should be used to remove pressure and aerosolized pharmaceuticals from the insufflated area. The HurriChem™ device should be operated in a direct flow operating room only. Use remote operation of the injection system to avoid unintended exposure to aerosolized solutions. Prevent unintended exposure or inhalation of aerosolized solutions by the patient and users. Contraindications: The HurriChem™ is not indicated for use in any other areas other than the intraperitoneal area, during laparoscopic operations. Do not use pharmaceutical or liquid solutions that are contraindicated for contact with medical grade stainless steel. Bibliography: Aiyami M, Hubner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368-e377. doi:10.1016/S1470-2045(19)30318-3

CE 1639

www.thermasolutions.com

Ref# MK-7519 Rev G (01/2023)